Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
NCT03094884
Recruiting
Phase I study with the hypothesis that Pulsed Low Dose Radiation (PLDR) radiation delivery technique can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy. For these patients, the rate of severe acute esophagitis during concurrent CRT is high (approximately 20%) when conventional external beam radiation is utilized. Severe acute esophagit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Esophageal Cancer
Register for Updates
Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications
NCT03773575
Recruiting
This study is a prospective, multi-center, two-arm, unblinded, and randomized controlled trial with a goal of evaluating the impact of a closed incision negative pressure dressing (PREVENA) on incidence of post-operative wound complications and medical costs in patients undergoing lower extremity amputation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2023
Locations: Thomas Jefferson University/Hospital, Philadelphia, Pennsylvania
Conditions: Amputation, Amputation; Postoperative, Sequelae, Wound Dehiscence, Seroma, Wound Infection, Surgical, Lymph Leakage
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-008 - MidLantic Urology, Bala-Cynwyd, Pennsylvania
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
NCT05588583
Recruiting
The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit. Participants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2023
Locations: Serena Group Research Institute, Pittsburgh, Pennsylvania
Conditions: Wounds, Wound of Skin, Wound Leg, Wound; Foot, Diabetic Foot Ulcer, Venous Leg Ulcer
Register for Updates
NuroSleeve Powered Brace & Stimulation System to Restore Arm Function
NCT04798378
Recruiting
The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one arm sufficient to perform daily activities. This study could lead to the development of a product that could allow people with arm weakness or arm paralysis to use the NuroSleeve and similar devices to improve arm health and independent function.
Gender:
ALL
Ages:
4 years and above
Trial Updated:
04/11/2023
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Allegheny Health Network (AHN) West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Register for Updates
Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss
NCT05180448
Recruiting
Adults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and support and ongoing opportunities to reflect with others on goal progress. This study proposes that sharing digital data with other parties has the potential to improve long-term weight loss. The proposed study will enroll adults ("index participants") (N = 320) with overweig... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/23/2023
Locations: Drexel University, Philadelphia, Pennsylvania
Conditions: Overweight, Obesity
Register for Updates
5-aminolevulinic Acid In Advanced Malignancies
NCT04443686
Recruiting
This is a phase 1, open label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study to determine the maximum tolerated doses (MTD) or recommended phase 2 doses (RP2D) of both ALA and RT. Once the MTDs are identified, the cohort providing the highest dose intensity at or below the MTD (if supported by emerging PK and biomarker data) will be selected for an expansion phase for the purpose of refining the safety assessment and assessing preliminary efficacy. The initial dose escalati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy
NCT05274230
Recruiting
The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Apollo Neuroscience, Inc., Pittsburgh, Pennsylvania
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
Rett Syndrome Registry
NCT05432349
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Register for Updates
Knee Related Subchondral Bone Lesions Treated With IOBP
NCT05314608
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania
Conditions: Subchondral Cyst
Register for Updates